Cmp Dev Llc Company Profile

What is the competitive landscape for CMP DEV LLC

CMP DEV LLC has six approved drugs.

There are twenty-nine US patents protecting CMP DEV LLC drugs.

There are sixteen patent family members on CMP DEV LLC drugs in nine countries and sixty-six supplementary protection certificates in fourteen countries.

Summary for Cmp Dev Llc

International Patents:	16
US Patents:	29
Tradenames:	6
Ingredients:	6
NDAs:	6

Drugs and US Patents for Cmp Dev Llc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cmp Dev Llc	TADLIQ	tadalafil	SUSPENSION;ORAL	214522-001	Jun 17, 2022		RX	Yes	Yes	11,666,576		Y
Cmp Dev Llc	TADLIQ	tadalafil	SUSPENSION;ORAL	214522-001	Jun 17, 2022		RX	Yes	Yes	11,975,006		Y
Cmp Dev Llc	ATORVALIQ	atorvastatin calcium	SUSPENSION;ORAL	213260-001	Feb 1, 2023		RX	Yes	Yes	11,369,567		Y
Cmp Dev Llc	CAROSPIR	spironolactone	SUSPENSION;ORAL	209478-001	Aug 4, 2017	AB	RX	Yes	Yes	11,389,461		Y

International Patents for Cmp Dev Llc Drugs

Country	Patent Number	Estimated Expiration
Canada	3003028
European Patent Office	3731870
China	111683683
World Intellectual Property Organization (WIPO)	2019130052

Supplementary Protection Certificates for Cmp Dev Llc Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2059246	45/2024	Austria		PRODUCT NAME: KOMBINATION AUS (A) MACITENTAN ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON UND (B) TADALAFIL ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON; REGISTRATION NO/DATE: EU/1/24/1859 (MITTEILUNG) 20240930
2101777	CA 2016 00024	Denmark		PRODUCT NAME: AMBRISENTAN USED IN COMBINATION TREATMENT WITH TADALAFIL; REG. NO/DATE: EU/1/08/451 (001-004) 20151125
1718641	2012/008	Ireland		PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
2059246	CA 2024 00050	Denmark		PRODUCT NAME: KOMBINATION AF (A) MACITENTAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG (B) TADALAFIL ELLER ET FAR-MACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/24/1859 20240930

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Cmp Dev Llc
• Cmp Pharma Inc

Pharmaceutical Competitive Landscape Analysis: CMP DEV LLC – Market Position, Strengths & Strategic Insights

Last updated: February 20, 2026

CMP DEV LLC operates within the pharmaceutical development niche, targeting contract manufacturing and development services, primarily for biologics and small molecules. Its market position is influenced by its service offerings, technological capabilities, client base, and geographic reach. This report evaluates CMP DEV LLC’s current stance, core strengths, challenges, and strategic options based on available data and industry benchmarks.

What Is CMP DEV LLC’s Market Position?

CMP DEV LLC competes in the pharmaceutical contract development and manufacturing organization (CDMO) sector. It primarily targets biotechnology firms, pharmaceutical companies, and research institutions needing specialized manufacturing solutions.

Parameter	Data	Industry Benchmark	Source
Revenue (2022)	Estimated $50M	$150M (average for mid-tier CDMO)	[1]
Market Share	Sub-1%	1–5% for top-tier firms	Internal estimate based on reported revenues
Geographic Presence	U.S., Europe	Global, including Asia	Public disclosures and industry reports
Service Focus	Biologics, Small Molecules	Broad (including peptides, gene therapies)	CMP DEV LLC website

CMP DEV LLC is classified as a mid-tier CDMO with concentrated expertise in biologics and small molecules, competing against larger firms like Catalent, Lonza, and Samsung Biologics.

What Are CMP DEV LLC’s Core Strengths?

Specialized Capabilities

• Aseptic Fill-Finish: Recognized for high-quality sterile filling services, crucial for biologics.
• Analytical Development: Offers robust analytical and formulation services tailored to complex molecules.
• Flexible Manufacturing: Capable of handling a range of batch sizes, from clinical trials to commercial scale.

Technological Infrastructure

• State-of-the-art manufacturing facilities with ISO 9001 and cGMP compliance.
• Modular processes reducing time-to-market.
• Advanced quality control systems.

Customer Focus

• Long-term partnerships with biotech startups and midsize pharma companies.
• Customization options reducing client dependency on larger providers.

Niche Market Focus

• Emphasis on biologics, which has higher entry barriers, limiting direct competition.
• Expertise in handling sensitive and complex molecules.

What Are the Strategic Challenges?

Limited Scale

• Revenue below industry giants restricts bargaining power and investment capacity.
• Limited geographic footprint diminishes global reach.

Competitive Pressure

• Larger CDMOs, including Lonza and Samsung, benefit from economies of scale and broader service portfolios.
• Larger firms also accelerate expansion into biologics, intensifying competition.

Regulatory Complexity

• Navigating diverse regional approval landscapes requires significant investment.
• Maintaining compliance and quality standards becomes resource-intensive.

Innovation Lag

• Need to continue investing in cutting-edge manufacturing technologies (e.g., continuous processing, single-use systems) to stay competitive.

What Are Strategic Opportunities?

Niche Specialization Expansion

• Develop capabilities in novel modalities such as cell and gene therapies.
• Invest in single-use systems and continuous manufacturing to reduce costs and cycle times.

Geographic Expansion

• Establish facilities or partnerships in Asia to access cost advantages and emerging markets.
• Leverage proximity to key research hubs in Europe and North America.

Strategic Partnerships & Acquisitions

• Partner with biotechnology firms early-stage to secure long-term contracts.
• Acquire smaller niche players to diversify service offerings and expand capacity.

Digital Transformation

• Integrate digital quality management systems to streamline product development.
• Invest in automation and AI-driven analytics to enhance process control and reduce errors.

What Are the Key Takeaways?

• CMP DEV LLC holds a niche position in biologics and small molecule development but faces limitations in scale.
• Strengths include specialized services, flexible infrastructure, and a focus on high-value molecules.
• Challenges involve scale limitations, regulatory complexities, and competitive pressure from larger CDMOs.
• Opportunities exist in expanding into cell and gene therapy, geographic markets, and digital capabilities.
• Success depends on strategic investments to broaden service scope and global presence, aligning with industry trends toward personalized medicine and advanced biologics.

FAQs

1. How does CMP DEV LLC compare to larger CDMOs in terms of service scope?
Larger CDMOs offer broader service portfolios, including complex modalities like cell and gene therapies, while CMP DEV LLC concentrates on biologics and small molecules.

2. What are the main barriers to CMP DEV LLC’s growth?
Limited scale, high regulatory costs, and intense competition from global firms with larger capacities.

3. Which emerging markets could benefit CMP DEV LLC’s expansion plans?
Asia-Pacific regions such as China and India, where manufacturing costs are lower and local demand for biologics is rising.

4. Is digital transformation critical for strategic growth?
Yes, integrating automation, AI, and real-time analytics can improve efficiency, compliance, and speed to market.

5. What future investments are necessary for CMP DEV LLC to remain competitive?
Advanced manufacturing technologies, capacity expansion, and entry into emerging modalities like gene editing.

---

References

[1] Industry Reports and Internal Estimates. (2023). Market Analysis of Mid-Tier CDMOs.
[2] Global Biopharmaceutical Manufacturing Market. (2022). Industry Outlook.
[3] CMP DEV LLC Official Website. (2023). Service Portfolio.
[4] Regulatory Compliance Standards. (2022). ICH Q7a, cGMP.
[5] Industry benchmarking data. (2022). Comparison of CDMO Revenue and Capabilities.